All (2)News (2)Transcripts (0)Press Releases (0)

News138 days ago

RxSight Faces Multiple Downgrades Amid Revenue Shortfall

RxSight shares are trading lower after Piper Sandler, BofA Global Research, and Wells Fargo all downgraded the stock, cutting their price targets to $10, $9, and $9 respectively, following the company's lower-than-expected Q2 results and reduced FY25 guidance.

News139 days ago

RxSight Shares Decline After Revenue Guidance Cut

RxSight shares are trading lower after the company announced preliminary Q2 results and lowered its full-year 2025 revenue guidance.